公开(公告)号：KR1020140123264A

公开(公告)日：2014-10-22

申请号：KR1020130040342

申请日：2013-04-12

Applicant: 동화약품주식회사

Inventor： 장환봉 ,  윤주병 ,  이현용 ,  노양국

IPC: A61K31/05 ,  A61K31/045 ,  A61K36/605 ,  A61P3/10

CPC classification number: A61K36/605 ,  A23L33/105 ,  A61K31/352

Abstract: The present invention relates to a pharmaceutical composition or health functional food comprising cathayanin B or kuwanol A, which are compounds isolated from morus bark, for preventing and treating diabetic complications. According to the present invention, the cathayanin B compound is isolated from the morus bark, and inhibits the creation of an advanced glycation end-product (AGE), which is a causative substance of diabetic complications, and aldose reductase activity. Thus, the pharmaceutical composition or health functional food, which comprises the cathayanin B or the kuwanol A, can be useful for inhibiting diabetic complications such as diabetic nephropathy, diabetic retinopathy and diabetic neuropathy. In particular, the kuwanol A can be used as the pharmaceutical composition for preventing and treating various fibrosis and cancer metastasis as well as the diabetic complications and also used as the health functional food for alleviating the same.

Abstract translation: 本发明涉及一种药物组合物或保健功能食品，其包含作为从桑树皮分离的化合物，用于预防和治疗糖尿病并发症的cathayanin B或kuwanol A。 根据本发明，从桑树皮中分离出cathayanin B化合物，抑制作为糖尿病并发症的致病物质的高级糖基化终产物（AGE）的产生和醛糖还原酶的活性。 因此，包含cathayanin B或kuwanol A的药物组合物或健康功能性食品可用于抑制糖尿病性肾病，糖尿病性视网膜病变和糖尿病性神经病变等糖尿病并发症。 特别地，可以将奎娃子A用作预防和治疗各种纤维化和癌症转移以及糖尿病并发症的药物组合物，并且也用作用于缓解其的健康功能性食品。

公开(公告)号：KR101011333B1

公开(公告)日：2011-01-28

申请号：KR1020060009292

申请日：2006-01-31

Applicant: 동화약품주식회사

Inventor： 유제만 ,  임문정 ,  노양국 ,  장환봉 ,  오성준 ,  이현용 ,  구세광 ,  양희복 ,  이정우 ,  김윤중 ,  윤주병

IPC: A61K36/488 ,  A61K36/237 ,  A61K36/9068 ,  A61P13/12

CPC classification number: A61K36/25 ,  A61K36/488 ,  A61K36/60 ,  A61K2300/00

Abstract: 본 발명은 생약재 갈근(Puerariae Radix), 백강잠(Bombycis corpus) 또는 독활(Araliae Continentalis Radix)중에서 1 이상 선택되는 생약 추출물을 함유하는 의약 및 건강기능식품에 관한 것이다. 본 발명에 따른 생약재는 독립적으로 또는 혼합조성물로 하여 신장질환 예방 및 치료 또는 신장기능 개선을 위해 유용하게 이용될 수 있다.
갈근, 백강잠, 독활, 신장질환

公开(公告)号：KR1020120111771A

公开(公告)日：2012-10-11

申请号：KR1020110027789

申请日：2011-03-28

Applicant: 동화약품주식회사

Inventor： 장환봉 ,  윤주병 ,  이현용 ,  최현식 ,  이형복

IPC: A61K36/605 ,  A61K31/36 ,  A61P3/10

CPC classification number: A61K31/352 ,  A23L33/10 ,  A61K31/05 ,  A61K31/353

Abstract: PURPOSE: A final glycosylation product inhibitor or health functional food is provided to suppress development of diabetic complication. CONSTITUTION: A final glycosylation product inhibitor which suppresses the development of diabetes complication contains mulberrofuran G isolated from Morus bark, mulberrofuran K, kuwanon G, kuwanon Z, oxyresveratrol, 2',4',5,7-tetrahydroxyflavanone, morusignin L, or dihydromorin as an active ingredient. The diabetic complication includes diabetic splenocyte nephritis, diabetic retinopathy or diabetic splenocyte neuropathic disease. [Reference numerals] (1) Normal group(-20°C); (10) Morusignin-L; (11) Dihydromorin; (2) Control group(37°C); (3) Pyridoxamine(positive control group); (4) Mulberrofuran-G; (5) Mulberrofuran-K; (6) Kuwanon-G; (7) Kuwanon-Z; (8) 2'.4'.5.7-tetrahydroxyflavanone; (9) Oxyresveratrol; (AA) Anti-AGEs antibody; (BB) Anti-CML antibody; (CC) Ponseau S staining

Abstract translation: 目的：提供最终的糖基化产物抑制剂或保健功能食品来抑制糖尿病并发症的发展。 构成：抑制糖尿病并发症发展的最终糖基化产物抑制剂含有从桑树皮，多杀龙furan酮K，kuwanon G，kuwanon Z，氧基白藜芦醇，2'，4'，5,7-四羟基黄烷酮，morusignin L或二氢肌醇 作为活性成分。 糖尿病并发症包括糖尿病性脾细胞性肾炎，糖尿病性视网膜病变或糖尿病脾细胞性神经病变。 （附图标记）（1）正常组（-20℃）; （10）Morusignin-L; （11）二氢吗啉; （2）对照组（37℃）; （3）吡哆胺（阳性对照组）; （4）芒果呋喃-G; （5）甲基呋喃-K; （6）Kuwanon-G; （7）Kuwanon-Z; （8）2'4'5.7-四羟基黄烷酮; （9）氧化维生素; （AA）抗AGEs抗体; （BB）抗CML抗体; （CC）Ponseau S染色